Description: Discover Gilead's HepConnect initiative aimed at addressing the intersecting opioid and HCV crises and rising hepatitis C infections in the greater Appalachian states.
ANNOUNCED : First round grantees selected. Learn more here .
HepConnect is a five-year, multi-million-dollar initiative aimed at addressing the increase in hepatitis C (HCV) infections. In partnership with local organizations, the initiative will develop and implement evidence-based solutions to meet the needs of people most affected by the opioid crisis.
To address growing HCV infection rates in greater Appalachia, HepConnect has three areas of focus: